Valuation: Guided Therapeutics Inc

Market Cap 28M 24.23M 22.59M 20.79M 39.23M 2.66B 39.68M 265M 104M 1.33B 105M 103M 4.42B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 30.87M 26.72M 24.91M 22.92M 43.25M 2.94B 43.75M 293M 115M 1.47B 116M 113M 4.87B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 2023-03-05
Chief Tech/Sci/R&D Officer 70 2010-12-01
Director TitleAgeSince
Director/Board Member 70 2016-11-30
Director/Board Member 76 2006-04-09
Chairman 67 2013-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+2.32%+0.25%+23.85%+5.32% 209B
+2.51%+0.31%+1.11%-21.63% 137B
+1.88%+3.70%-22.38%+21.30% 130B
-2.75%+3.65%-55.30%-5.88% 71.14B
-0.70%+6.32%+11.09%+11.84% 51.59B
+0.62%+9.24%-15.14%-20.39% 49.99B
+1.37%+0.41%+22.88%+11.73% 39.31B
+0.99%+4.19%+40.06%+37.98% 38.89B
+0.40%+7.21%-23.13%+24.98% 32.19B
Average +0.56%+3.19%-1.88%+7.25% 84.33B
Weighted average by Cap. +1.01%+1.42%-0.24%+3.74%

Financials

2024 2025
Net sales 7K 6.06K 5.65K 5.2K 9.81K 666K 9.92K 66.37K 26.03K 333K 26.29K 25.71K 1.1M 767K 664K 619K 570K 1.07M 72.95M 1.09M 7.27M 2.85M 36.48M 2.88M 2.82M 121M
Net income -2.42M -2.09M -1.95M -1.79M -3.39M -230M -3.43M -22.92M -8.99M -115M -9.08M -8.88M -381M -3.2M -2.77M -2.58M -2.37M -4.48M -304M -4.53M -30.3M -11.88M -152M -12M -11.74M -504M
Net Debt 1.77M 1.53M 1.43M 1.32M 2.48M 168M 2.51M 16.79M 6.58M 84.24M 6.65M 6.5M 279M 2.88M 2.49M 2.32M 2.14M 4.03M 274M 4.08M 27.27M 10.69M 137M 10.8M 10.56M 454M
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-